Informatie:
Fout:
ID
34149
Beschrijving
PET/CT Guided Fulvestrant Therapy for Patients With Recurrent or Metastatic Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00816582
Link
https://clinicaltrials.gov/show/NCT00816582
Trefwoorden
Versies (1)
- 14-01-19 14-01-19 -
Houder van rechten
GSK group of companies
Geüploaded op
14 januari 2019
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Breast Cancer NCT00816582
Eligibility Breast Cancer NCT00816582
- StudyEvent: Eligibility
Similar models
Eligibility Breast Cancer NCT00816582
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
ID.1
Item
post-menopausal (≥ 60 years old, or age ≥ 45 years with amenorrhea for > 12 months or follicle stimulating hormone and estrogen levels within post-menopausal range, or prior bilateral oophorectomy)
boolean
ID.2
Item
hormone receptor positive (er and/or pgr) disease as determined locally
boolean
ID.3
Item
who performance status 0-2
boolean
ID.4
Item
life expectancy of ≥ 3 months
boolean
ID.5
Item
the presence of at least one measurable or evaluable (non-measurable) lesion
boolean
ID.6
Item
informed consent prior to any study procedures
boolean
ID.7
Item
life threatening metastatic visceral disease
boolean
ID.8
Item
brain or leptomeningeal metastases
boolean
ID.9
Item
prior exposure to fulvestrant
boolean
ID.10
Item
history of bleeding diathesis or need for long term anti-coagulation
boolean